RAD51D and ovarian carcinoma: GPVs are associated with varying estimated lifetime risk of developing ovarian cancer: BRCA1 44% (95% CI, 36–53%), BRCA2 17% (11–25%) [42], RAD51C 11% (6–21%), RAD51D 13% (7–23%) [43], MLH1, MSH2 and MSH6 (LS) 11% (7.4–19.7%), 17.4% (11.8–31.2%) and 10.8% (3.7–38.6%), respectively [34], PALB2 ~5% (2–10%) and BRIP1 5.8% (3.6–9.1%) [34, 44].